Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring

Autor(es)

Portilho, Amanda Izeli ; da Costa, Hernan Hermes Monteiro ; Guereschi, Marcia Grando ; Prudencio, Carlos Roberto ; De Gaspari, Elizabeth

• Tipo de documento: Artigo Científico
• Fonte: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 20, n. 1, p. 11-pg., 2024-12-31.

Resumo

COVID-19, caused by SARS-CoV-2, and meningococcal disease, caused by Neisseria meningitidis, are relevant infectious diseases, preventable through vaccination. Outer membrane vesicles (OMVs), released from Gram-negative bacteria, such as N. meningitidis, present adjuvant characteristics and may confer protection against meningococcal disease. Here, we evaluated in mice the humoral and cellular immune response to different doses of receptor binding domain (RBD) of SARS-CoV-2 adjuvanted by N. meningitidis C:2a:P1.5 OMVs and aluminum hydroxide, as a combined preparation for these pathogens. The immunization induced IgG antibodies of high avidity for RBD and OMVs, besides IgG that recognized the Omicron BA.2 variant of SARS-CoV-2 with intermediary avidity. Cellular immunity showed IFN-gamma and IL-4 secretion in response to RBD and OMV stimuli, demonstrating immunologic memory and a mixed Th1/Th2 response. Offspring presented transferred IgG of similar levels and avidity as their mothers. Humoral immunity did not point to the superiority of any RBD dose, but the group immunized with a lower antigenic dose (0.5 mu g) had the better cellular response. Overall, OMVs enhanced RBD immunogenicity and conferred an immune response directed to N. meningitidis too. (AU)

• Processo FAPESP: 18/04202-0 - Estudo da imunogenicidade de antígenos de membrana externa de Neisseria meningitidis e interação com lípides catiônicos: avaliação de novo adjuvante para Neisseria meningitidis em diferentes linhagens de camundongos idosos
• Beneficiário: Elizabeth Natal de Gaspari
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/11936-3 - Centro de Ciência Translacional e Desenvolvimento de Biofármacos
• Beneficiário: Benedito Barraviera
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Ciência para o Desenvolvimento
• Processo FAPESP: 22/05566-1 - Construção e seleção de uma biblioteca de anticorpos monoclonais scFv contra a proteína spike do SARS-CoV-2 pela tecnologia de Phage Display
• Beneficiário: Hernan Hermes Monteiro da Costa
• Modalidade de apoio: Bolsas no Brasil - Doutorado